LOWM
ABBV icon

Laurel Oak Wealth Management’s AbbVie ABBV Stock Holding History

Laurel Oak Wealth Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$979K Buy
3,889
+224
+6% +$48.2K 0.14% 127
2026
Q1 		$797K Sell
3,665
-453
-11% -$100K 0.13% 133
2025
Q4 		$941K Buy
+4,118
New +$938K 0.16% 113

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Laurel Oak Wealth Management's ABBV Position: Q2 2026 in Review

Laurel Oak Wealth Management increased its AbbVie (ABBV) stake by 6.1% in Q2 2026, buying an estimated $48.2K and bringing the position to 3,889 shares worth $979K. The position accounts for 0.14% of the portfolio, ranked #127.

Laurel Oak Wealth Management first reported a position in ABBV in Q4 2025 and has held it in 3 quarters since. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Laurel Oak Wealth Management held 3,889 shares of AbbVie worth $979K as of Q2 2026.
  • Laurel Oak Wealth Management bought 224 AbbVie shares in Q2 2026, an estimated $48.2K.
  • AbbVie made up 0.14% of Laurel Oak Wealth Management's portfolio in Q2 2026, its #127 holding.
  • Laurel Oak Wealth Management first reported a position in AbbVie in Q4 2025 and has held it in 3 quarters since.
  • 4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Laurel Oak Wealth Management's 13F filing for Q2 2026, filed 21 Jul 2026.